PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer

Prior treatment

• Prior treatment for ESCC, including chemotherapy, radiotherapy, or prior antibody or drug therapy against PD-1, anti-PD-L1, anti-PD-L2, or any other specific T-cell costimulation or checkpoint pathway;
• They are not eligible to receive platinum-containing double-drug chemotherapy regimen, chemoradiotherapy or surgery;

Other illness

• Patients with other malignant tumors;
• Patients with a history of fistulas caused by primary tumor infiltration, patients assessed by the investigator as being at high risk of fistulas or showing signs of perforation, and severe malnutrition;
• Known human immunodeficiency virus (HIV) testing history or known acquired immunodeficiency syndrome (AIDS);
• A history of interstitial lung disease, non-infectious pneumonia or poorly controlled lung disease (including pulmonary fibrosis, acute lung disease, etc.);
• Any positive test result for hepatitis B virus or hepatitis C virus indicating the presence of a virus, such as hepatitis B surface antigen (HBsAg, Australian antigen) positive or hepatitis C antibody (anti-HCV) positive (except HCV-RNA negative);
• Those who have a history of drug abuse and cannot abstain or have mental disorders;
• Known history of allogeneic organ transplantation or allohematopoietic stem cell transplantation;
• Other conditions that the researchers believe will affect the progress of the study.

Other

• Poorly controlled pleural effusion, pericardial effusion or ascites requiring frequent drainage (recurrence within 2 weeks after intervention)
• Patients who are participating in other clinical trials or participating in other clinical trials with less than 4 weeks to end;
• Pregnant or lactating women;
• Patients with a BMI \< 18.5mg/m2 or a weight loss greater than 10% before screening;

• ≥18 years old;
• Pathology (histology) confirmed potentially resectable stage cT1-2N + M0 and stage cT3NanyM0 ESCC (AJCC 8th edition); 3. Received tirelizumab combined with chemotherapy before surgery; 4.ECOG score: 0 or 1; 5. R0 radical excision can be performed; 6. Measurable or evaluable lesions assessed by the investigator according to RECIST version 1.1; 7. With my consent and signed informed consent, I shall comply with the planned visit, research treatment, laboratory examination and other test procedures.